FDA Center for Devices and Radiological Health

Last updated
CDRH
FDA Bldg 62 - Exterior (5161375340).jpg
FDA White Oak Building 62
Center overview
Formed1982
Preceding agencies
  • Bureau of Medical Devices
  • Bureau of Radiological Health
Jurisdiction HHS
HeadquartersWhite Oak Campus; Silver Spring, MD
Employees2,230 (2023) [1]
Center executive
  • Michelle Tarver M.D., Ph.D, Director
Website FDA CDRH

The Center for Devices and Radiological Health (CDRH) is one of six product centers of the U.S. Food and Drug Administration (FDA), an agency that is part of the U.S. Department of Health and Human Services (HHS). CDRH is responsible for ensuring that patients and providers in the U.S. have timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products.

Contents

Examples of products that CDRH regulates include medical devices ranging from tongue depressors and personal protective equipment (PPE) to pacemakers and robotic surgical systems, and medical and non-medical radiation-emitting electronic products such as lasers, x-ray systems, ultrasound equipment, microwave ovens, and color televisions.

As of October 2024, the Director of CDRH is Michelle Tarver M.D., Ph.D.

Organization structure

CDRH is consists of seven offices that work in collaboration to assure that consumers have access to safe and effective medical products.

Office of Product Evaluation and Quality

The Office of Product Evaluation and Quality (OPEQ), one of the seven offices in CDRH, is structured to monitor the entirety of a medical product's evolution. Pre-market and post-market teams work together to evaluate the safety and effectiveness of medical devices. OPEQ houses the Office of Health Technologies (OHT), which is further subdivided into 8 offices by device type. Each office performs reviews of products over their lifecycle.

Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental DevicesOHT1Examples: contact lenses, snoring/sleep devices, dental ceramics
Office of Cardiovascular DevicesOHT2Examples: pacemakers, heart valves, ECGs, AEDs
Office of Gastrorenal, ObGyn, General Hospital, and Urology DevicesOHT3Examples: hemodialysis machines, tampons, IUDs
Office of Surgical and Infection Control DevicesOHT4Examples: robotic surgery devices, wound care devices
Office of Neurological and Physical Medicine DevicesOHT5Examples: cerebral stents, BCI devices, cerebral aneurysm clips
Office of Orthopedic DevicesOHT6Examples: hip replacement implants, orthopedic plates, orthopedic screws
Office of In Vitro DiagnosticsOHT7Examples: COVID-19 tests, pregnancy tests, HIV diagnostic tests
Office of Radiological HealthOHT8Examples: MRI machines, x-ray systems, microwaves

History

Medical devices first came under comprehensive regulation with the passage of the Federal Food, Drug, and Cosmetic Act of 1938 (FD&C), [9] which replaced the earlier Pure Food and Drug Act of 1906. The FD&C allowed the FDA to perform factory inspections and prohibited misbranded marketing of cosmetic and therapeutic medical devices. [10]

In the 1970s, Congress responded to the public's desire for additional oversight over medical devices by passing the Medical Device Amendments of 1976 (MDA) to the FD&C. The MDA established a risk-based framework for the classification of medical devices and a regulatory pathway for medical devices to get to the market, created a regulatory pathway for medical device clinical trials, and established several post-market requirements including manufacturer registration and device listing with the FDA, good manufacturing practices (GMPs), and reporting of adverse events.

Another predecessor of CDRH was the Public Health Service's Division of Radiological Health, which was formed in the late 1950s within the Environmental Health Divisions of the Bureau of State Services. [11] In 1970, as part of the Public Health Service reorganizations of 1966–1973, this division was split, with part going to the new Environmental Protection Agency [12] [13] and part moving into FDA. [14]

In 1982, the organizational units at the FDA that regulated medical devices and radiation-emitting products merged to form the Center for Devices and Radiological Health (CDRH).

Former leaders of CDRH [15]

Medical Device Legislation Milestones

CDRH mission and vision

The CDRH vision is that patients in the U.S. have access to high-quality, safe, and effective medical devices. CDRH works diligently to advance and interweave innovation and safety priorities to fulfill the mission of protecting and promoting public health.

Strategic priorities

In order to maintain and continuously improve the vision for high-quality safe and effective medical devices for all patients, CDRH regularly develops strategic priorities. [16] The following were established for 2022 – 2025.

Promote a Modern and Diverse Workforce: CDRH strives to prepare the organization so it is exceedingly proactive, flexible, resilient, collaborative, and engaged.

Enhance Organizational Agility and Resilience: CDRH makes efforts to adapt and redesign business processes, approaches, and policies to anticipate the needs of the future.

Advance Health Equity : CDRH aims to advance the development of knowledge and safe and effective technologies to meet the needs of all patients and consumers.

CDRH initiatives

Continuing partnerships with patients

  • CDRH advances the collection of scientific evidence about patient experience through the Patient Science and Engagement Program, and more recently with the creation of the Division for Patient-Centered Development. [17] CDRH proactively integrates these patient perspectives into the entirety of medical device review. CDRH promotes patient-centric clinical trials and the use of patient-reported outcome (PRO) data to foster access to new devices that meet patients’ needs. As of 2024, PROs were included in 52% of authorizations with clinical studies, with 34% using PROs as the primary and secondary clinical endpoints.
  • CDRH created the Patient Engagement Advisory Committee (PEAC), [18] the first and only advisory committee whose members are all patients, caregivers, and patient advocates. This advisory committee has held 7 meetings since 2017 and has provided recommendations on complex issues, including patient engagement in clinical trial design and conduct, use of patient-generated health data in post-market surveillance, communications about medical devices, such as communications regarding cybersecurity vulnerabilities, AR/VR and AI/ML in medical devices, and most recently advancing health equity in medical devices in 2023.
  • CDRH provides patients and caregivers with an opportunity to share their experiences living with a condition or using medical devices with CDRH staff through the Patient and Caregiver Connection. [19] There are approximately 20 Patient and Caregiver Connection Partner Organizations reflecting different medical specialties and cross-cutting topics. Partners include The Michael J. Fox Foundation, Breakthrough T1D, and Mended Hearts.
  • Collaborative Communities bring public and private sector members together to address health care challenges. CDRH currently participates in 17 collaborative communities, [20] including the National Evaluation System for Health Technology Coordinating Center (NESTcc) Collaborative Community (NESTcc) that aims to strategically leverage real-world evidence in the innovation of medical devices and the Heart Valve Collaboratory (HVC) to help patients with heart valve disease achieve their fullest potential for health.

Initiatives to encourage innovation and collaboration with innovators

  • The Breakthrough Devices Program [21] and Safer Technologies Program (STeP) [22] programs facilitate timely access to life-saving devices by expediting regulatory review. Devices granted a designation qualify for priority review and active engagement of senior management. CDRH has authorized over 100 devices through the Breakthrough Devices Program since program launch in 2015 and 2 devices through the STeP Program since program launch in 2021.
  • The Safety and Performance Based Pathway Program [23] ensures better quality devices on the market by allowing innovators to assess devices against performance criteria as opposed to outdated predicates. This option is available for 10 device areas for which guidances have been published.
  • The Digital Health Center of Excellence (DHCoE) [24] empowers interested parties to advance health care by fostering responsible and high-quality digital health innovation. The DHCoE provides centralized expertise and serves as a resource for digital health technologies and policy for digital health innovators, the public, and FDA staff. More than 700 AI/ML-enabled devices have been authorized since the center's launch in 2020.
  • In early 2023, CDRH launched the Total Product Life Cycle Advisory Program (TAP) [25] under MDUFA V to proactively help innovators navigate the journey from concept to commercialization. To date, there are 50 cardiovascular, neurological, and physical medicine devices participating in TAP. CDRH intends to enroll more innovators and their devices across a broader range of clinical disciplines, with a goal of enrolling up to 325 by 2027.
  • The use of peer-reviewed Regulatory Science Tools (RSTs) [26] allows innovators to efficiently navigate the design and redesign loop and expedite medical device innovation. The tools include methods, models, datasets and clinical outcome assessments based on the most innovative science. There are currently more than 150 tools in the catalog, with more than 20 new tools added every year. To date, more than 1,250 premarket submissions covering over 500 different product codes have cited use of RSTs.
  • In 2024, CDRH launched the groundbreaking Home as a Healthcare Hub [27] initiative to reimagine healthcare delivery and facilitate the adoption of devices that will establish the home as an integral part of the healthcare system. CDRH is co-creating a prototype home model with an architectural firm, patient groups, healthcare providers, and the medical device industry. This home prototype is necessary to facilitate meaningful innovation in home use devices by jump starting the community in conversation. The prototype is anticipated to be completed in late 2024.

Initiatives to encourage safety and quality

  • Based on a 2011 report [28] concluding that firms that proactively manage risks have fewer complaints and investigations, and often have lower quality-related costs, FDA launched the Case for Quality Program (CfQ). [29] CfQ includes various initiatives and pilots to further CDRH's goal of improving device quality, including the Voluntary Improvement Program (VIP), in which participating companies continue to show a downward trend in medical device recalls.
  • Globally, CDRH fosters quality and enables harmonization of quality management system requirements across regulatory jurisdictions. In early 2024, FDA issued a final rule [30] amending the device current good manufacturing requirements to align more closely with the international consensus standards set by International Organization for Standardization (ISO).
  • Established during the COVID-19 public health emergency, the Office of Supply Chain Resilience (OSCR) [31] within OST strengthens public health supply chains by proactively working with manufacturers, distributors, health care providers and other interested parties to prevent and mitigate shortages and improve the resiliency of the U.S. medical device supply chain.
  • Cybersecurity threats to the healthcare sector may lead to patient harm as a result of delay in diagnoses and/or treatment. The CDRH cybersecurity vision is to protect patient safety by strengthening medical device resiliency to cybersecurity threats. CDRH provides manufacturers with recommendations to integrate cybersecurity throughout the medical device design process and simultaneously issues safety communications to the public about cybersecurity vulnerabilities when needed.

Initiatives to enhance regulatory flexibility

  • CDRH continues to strengthen and streamline the clinical trial program to make it more attractive for industry to perform studies in the U.S. such that patients have earlier access to innovative technologies. Since 2009 CDRH has decreased the median time to clinical trial (Investigational Device Exemption) authorization by 90%.
  • CDRH strives to promote the use of Real-World Date and Evidence (RWE) [32] in place of conventional clinical trial data to reduce time to answer important device questions. CDRH has authorized more than 100 devices using RWE.

Related Research Articles

<span class="mw-page-title-main">Biomedical engineering</span> Application of engineering principles and design concepts to medicine and biology

Biomedical engineering (BME) or medical engineering is the application of engineering principles and design concepts to medicine and biology for healthcare applications. BME is also traditionally logical sciences to advance health care treatment, including diagnosis, monitoring, and therapy. Also included under the scope of a biomedical engineer is the management of current medical equipment in hospitals while adhering to relevant industry standards. This involves procurement, routine testing, preventive maintenance, and making equipment recommendations, a role also known as a Biomedical Equipment Technician (BMET) or as a clinical engineer.

<span class="mw-page-title-main">Food and Drug Administration</span> United States federal agency

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

Medical software is any software item or system used within a medical context, such as reducing the paperwork, tracking patient activity

<span class="mw-page-title-main">Good manufacturing practice</span> Manufacturing quality standards

Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use.

<span class="mw-page-title-main">Federal Food, Drug, and Cosmetic Act of 1938</span> Acts of the United States Congress

The United States Federal Food, Drug, and Cosmetic Act is a set of laws passed by the United States Congress in 1938 giving authority to the U.S. Food and Drug Administration (FDA) to oversee the safety of food, drugs, medical devices, and cosmetics. The FDA's principal representative with members of congress during its drafting was Charles W. Crawford. A principal author of this law was Royal S. Copeland, a three-term U.S. senator from New York. In 1968, the Electronic Product Radiation Control provisions were added to the FD&C. Also in that year the FDA formed the Drug Efficacy Study Implementation (DESI) to incorporate into FD&C regulations the recommendations from a National Academy of Sciences investigation of effectiveness of previously marketed drugs. The act has been amended many times, most recently to add requirements about bioterrorism preparations.

<span class="mw-page-title-main">Medical device</span> Device to be used for medical purposes

A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country. As a general rule, as the associated risk of the device increases the amount of testing required to establish safety and efficacy also increases. Further, as associated risk increases the potential benefit to the patient must also increase.

<span class="mw-page-title-main">Center for Veterinary Medicine</span> US FDA branch that regulates animal feed and medications

The Center for Veterinary Medicine (CVM) is a branch of the U.S. Food and Drug Administration (FDA) that regulates the manufacture and distribution of food, food additives, and drugs that will be given to animals. These include animals from which human foods are derived, as well as food additives and drugs for pets or companion animals. CVM is responsible for regulating drugs, devices, and food additives given to, or used on, over one hundred million companion animals, plus millions of poultry, cattle, swine, and minor animal species. Minor animal species include animals other than cattle, swine, chickens, turkeys, horses, dogs, and cats.

Title 21 is the portion of the Code of Federal Regulations that governs food and drugs within the United States for the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), and the Office of National Drug Control Policy (ONDCP).

Clinical research is a branch of medical research that involves people and aims to determine the effectiveness (efficacy) and safety of medications, devices, diagnostic products, and treatment regimens intended for improving human health. These research procedures are designed for the prevention, treatment, diagnosis or understanding of disease symptoms.

A patient safety organization (PSO) is a group, institution, or association that improves medical care by reducing medical errors. Common functions of patient safety organizations are data collection, analysis, reporting, education, funding, and advocacy. A PSO differs from a Federally designed Patient Safety Organization (PSO), which provides health care providers in the U.S. privilege and confidentiality protections for efforts to improve patient safety and the quality of patient care delivery

Postmarketing surveillance (PMS), also known as post market surveillance, is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market and is an important part of the science of pharmacovigilance. Since drugs and medical devices are approved on the basis of clinical trials, which involve relatively small numbers of people who have been selected for this purpose – meaning that they normally do not have other medical conditions which may exist in the general population – postmarketing surveillance can further refine, or confirm or deny, the safety of a drug or device after it is used in the general population by large numbers of people who have a wide variety of medical conditions.

<span class="mw-page-title-main">Center for Drug Evaluation and Research</span> US Food and Drug Administration division

The Center for Drug Evaluation and Research is a division of the U.S. Food and Drug Administration (FDA) that monitors most drugs as defined in the Food, Drug, and Cosmetic Act. Some biological products are also legally considered drugs, but they are covered by the Center for Biologics Evaluation and Research. The center reviews applications for brand name, generic, and over the counter pharmaceuticals, manages US current Good Manufacturing Practice (cGMP) regulations for pharmaceutical manufacturing, determines which medications require a medical prescription, monitors advertising of approved medications, and collects and analyzes safety data about pharmaceuticals that are already on the market.

<span class="mw-page-title-main">Office of Global Regulatory Operations and Policy</span>

The Office of Global Regulatory Operations and Policy (GO), also known as the Office of Regulatory Affairs (ORA), is the part of the U.S. Food and Drug Administration (FDA) enforcing the federal laws governing biologics, cosmetics, dietary supplements, drugs, food, medical devices, radiation-emitting electronic devices, tobacco products, and veterinary medicine products which may have potentially harmful side effects for the consumer.

<span class="mw-page-title-main">Food and Drug Administration Amendments Act of 2007</span> US law

President of the United States George W. Bush signed the Food and Drug Administration Amendments Act of 2007 (FDAAA) on September 27, 2007. This law reviewed, expanded, and reaffirmed several existing pieces of legislation regulating the FDA. These changes allow the FDA to perform more comprehensive reviews of potential new drugs and devices. It was sponsored by Reps. Joe Barton and Frank Pallone and passed unanimously by the Senate.

The following outline is provided as an overview of and topical guide to clinical research:

Critical Path Institute (C-Path) is a non-profit organization created to improve the drug development process; its consortia include more than 1,600 scientists from government regulatory and research agencies, academia, patient organizations, and bio-pharmaceutical companies.

<span class="mw-page-title-main">National Center for Health Research</span> Organization

The National Center for Health Research is a Washington, D.C. based non-profit organization founded in 1999. NCHR provides health-related services such as: free information and training based on research findings, educating policy makers and working with the media. The President of the organisation is Diana Zuckerman. The primary program is The Cancer Prevention and Treatment Fund, which utilises an online health hotline.

<span class="mw-page-title-main">Food and Drug Administration Safety and Innovation Act</span> Piece of American regulatory legislation

The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) is a piece of American regulatory legislation signed into law on July 9, 2012. It gives the United States Food and Drug Administration (FDA) the authority to collect user fees from the medical industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biologics. It also creates the breakthrough therapy designation program and extends the priority review voucher program to make eligible rare pediatric diseases. The measure was passed by 96 senators voting for and one voting against.

<span class="mw-page-title-main">Janet Woodcock</span> American physician

Janet Woodcock is an American physician who served as Principal Deputy Commissioner of Food and Drugs from February 2022 until February 2024, having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA). She joined the FDA in 1986, and has held a number of senior leadership positions there, including terms as the Director of Center for Drug Evaluation and Research (CDER) from 1994 to 2004 and 2007 to 2021.

Due to the many regulations in the industry, the design of medical devices presents significant challenges from both engineering and legal perspectives.

References

  1. ↑ "CDRH 2023 Annual Report". FDA. Food and Drug Administration. 3 April 2024. Retrieved October 25, 2024.
  2. ↑ "Office of the Center Director". Food and Drug Administration. August 2024. Retrieved October 25, 2024.
  3. ↑ "Office of Policy". Food and Drug Administration. 30 October 2023. Retrieved October 25, 2024.
  4. ↑ "Office of Strategic Partnerships and Technology Innovation". Food and Drug Administration. 24 January 2024. Retrieved October 25, 2024.
  5. ↑ "Office of Product Evaluation and Quality". Food and Drug Administration. 26 September 2024. Retrieved October 25, 2024.
  6. ↑ "Office of Communication, Information Disclosure, Training and Education". Food and Drug Administration. 16 July 2024. Retrieved October 25, 2024.
  7. ↑ "Office of Management". Food and Drug Administration. 23 January 2024. Retrieved October 25, 2024.
  8. ↑ "Office of Science and Engineering Laboratories". Food and Drug Administration. 24 September 2024. Retrieved October 25, 2024.
  9. ↑ "The History of Medical and Radiation-Emitting Device Regulation". FDA. Food and Drug Administration. 9 August 2024. Retrieved October 25, 2024.
  10. ↑ Schlauderaff, Abraham; Boyer, Kaleigh (May 9, 2019). "An Overview of Food and Drug Administration Medical Device Legislation and Interplay with Current Medical Practices". Cureus. 11 (5): e4627. doi: 10.7759/cureus.4627 . PMC   6615584 . PMID   31312553.
  11. ↑ Programs of the U.S. Department of Health, Education, and Welfare: An Executive Reference Book. U.S. Department of Health, Education, and Welfare. 1959. p. 27.
  12. ↑ "Records of the Environmental Protection Agency [EPA]". National Archives. 2016-08-15. Section 412.2. Retrieved 2021-04-23.
  13. ↑ "Reorganization Plan No. 3 of 1970". U.S. Environmental Protection Agency. Retrieved 2021-04-23.
  14. ↑ "CDRH Milestones". U.S. Food and Drug Administration. 2006-01-09. Retrieved 2020-08-29.
  15. ↑ "CDRH Leadership". Food and Drug Administration. Retrieved October 25, 2024.
  16. ↑ "CDRH Strategic Priorities and Updates". Food and Drug Administration. 5 August 2024. Retrieved October 25, 2024.
  17. ↑ "Division of Patient-Centered Development". Food and Drug Administration. 19 January 2024. Retrieved October 25, 2024.
  18. ↑ "CDRH Patient Engagement Advisory Committee". FDA. Food and Drug Administration. 24 September 2024. Retrieved October 25, 2024.
  19. ↑ "CDRH Patient and Caregiver Connection". FDA. Food and Drug Administration. 24 June 2024. Retrieved October 25, 2024.
  20. ↑ "Collaborative Communities: Addressing Health Care Challenges Together". FDA. Food and Drug Administration. 20 September 2024. Retrieved October 25, 2024.
  21. ↑ "Breakthrough Devices Program". FDA. Food and Drug Administration. 9 August 2024. Retrieved October 25, 2024.
  22. ↑ "Safer Technologies Program (SteP) for Medical Devices". FDA. Food and Drug Administration. 15 August 2023. Retrieved October 25, 2024.
  23. ↑ "Safety and Performance Based Pathway". Food and Drug Administration. Retrieved October 25, 2024.
  24. ↑ "Digital Health Center of Excellence". Food and Drug Administration. 26 September 2024. Retrieved October 25, 2024.
  25. ↑ "Total Product Life Cycle Advisory Program". Food and Drug Administration. Retrieved October 25, 2024.
  26. ↑ "Catalog of Regulatory Science Tools to Help Assess New Medical Devices". FDA. Food and Drug Administration. 26 September 2024. Retrieved October 25, 2024.
  27. ↑ "Home as a Health Care Hub". FDA. Food and Drug Administration. 6 August 2024. Retrieved October 25, 2024.
  28. ↑ "Understanding Barriers to Medical Device Quality" (PDF). Food and Drug Administration. Retrieved October 25, 2024.
  29. ↑ "Case for Quality". FDA. Food and Drug Administration. 9 August 2024. Retrieved October 25, 2024.
  30. ↑ "Federal Register Medical Devices; Quality System Regulation Amendments". Food and Drug Administration. 2 February 2024. Retrieved October 25, 2024.
  31. ↑ "Office of Supply Chain Resilience". FDA. Food and Drug Administration. April 2024. Retrieved October 25, 2024.
  32. ↑ "Real World Evidence". Food and Drug Administration. 19 September 2024. Retrieved October 25, 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.